title: RASopathic alopecia: hair changes associated with vemurafenib therapy.
authors.affiliation: Dermatology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Italy.
authors.forename: Bianca Maria
authors.initials: BM
authors.lastname: Piraccini
authors.affiliation: Dermatology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Italy.
authors.forename: Annalisa
authors.initials: A
authors.lastname: Patrizi
authors.affiliation: Dermatology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Italy.
authors.forename: Pier Alessandro
authors.initials: PA
authors.lastname: Fanti
authors.affiliation: Dermatology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Italy.
authors.forename: Michela
authors.initials: M
authors.lastname: Starace
authors.affiliation: Dermatology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Bruni
authors.affiliation: Medical Oncology Unit, Sant'Orsola Malpighi Hospital Bologna, Italy.
authors.forename: Barbara
authors.initials: B
authors.lastname: Melotti
authors.affiliation: Dermatology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Italy.
authors.forename: Cosimo
authors.initials: C
authors.lastname: Misciali
authors.affiliation: Dermatology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Italy. Electronic address: emi.dika3@unibo.it.
authors.forename: Emi
authors.initials: E
authors.lastname: Dika
mesh_terms: D000505:Alopecia / Q000139:chemically induced* / Q000473:pathology; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002990:Clobetasol / Q000627:therapeutic use; D005260:Female; D018859:Hair Follicle / Q000201:enzymology / Q000473:pathology; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000201:enzymology / Q000556:secondary*; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000502:physiology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D000077484:Vemurafenib
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D007211:Indoles; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000077484:Vemurafenib; D002990:Clobetasol; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf